Sermorelin
GHRH(1-29) analog studied for pituitary somatotroph stimulation and endogenous GH-axis signaling.
This product is not a drug, food, or cosmetic and is not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. By purchasing, you confirm you are a qualified researcher or institution acquiring this product solely for in-vitro laboratory research. See our Research Disclaimer for full terms.
Description
Sermorelin corresponds to the first 29 amino acids of endogenous growth hormone-releasing hormone — the shortest fragment retaining full GHRH receptor binding activity. Research on Sermorelin has focused on its action at pituitary somatotroph GHRH receptors, stimulating cAMP-PKA signaling and pulsatile GH release while preserving the hypothalamic-pituitary feedback loop, in contrast to exogenous GH administration. Its short plasma half-life relative to modified GHRH analogs like CJC-1295 has made it a reference compound in comparative GH-axis pharmacokinetic studies. Supplied for in-vitro laboratory research only — not for human or veterinary use.